The purpose of this study is to evaluate the metabolic and the safety outcomes in people living with pancreatic diabetes (pancreatitis or pancreatectomy-induced diabetes) and using a closed-loop insulin delivery systems ("artificial pancreas").
Secondary pancreatic diabetes is an unstable diabetes, due to deficiency in B cells which produce insulin, alpha cells which produce glucagon, and exorcrine insufficiency. Patients with secondary pancreatic diabetes are exposed to high glycemic variability and severe hypoglycemic episodes. Hybrid closed loop treatment has shown efficacy and safety for patients with type 1 diabetes and has the potential to improve the control of secondary pancreatic diabetes but has rarely been studied in this particular indication. A retrospective observational cohort study in patients will be contucted suffering from secondary pancreatic diabetes in whom this device was implemented in order to observe metabolic and safety outcomes compared to the period before they were treated with hybrid closed-loop system.
Study Type
OBSERVATIONAL
Enrollment
10
Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Centre Hospitalier Sud Francilien
Corbeil-Essonnes, Fra, France
Percentage of time spent in the target
Percentage of time spent in the target, between 70 and 180 mg/dl: 14 to 90 days before starting hybrid closed loop
Time frame: at day 0
Percentage of time spent in the target
Percentage of time spent in the target, between 70 and 180 mg/dl the last 90 days available (T1) after starting hybrid closed loop
Time frame: at day 90
Percentage of time spent
Percentage of time spent bellow 70 mg/dL (TBR for Time Bellow Range ) and Above 180 mg/dL (TAR for Time Above Range )
Time frame: at day 0
Percentage of time spent
Percentage of time spent bellow 70 mg/dL (TBR for Time Bellow Range ) and Above 180 mg/dL (TAR for Time Above Range )
Time frame: at day 90
Pourcentage of closed-loop mode use
Pourcentage of closed-loop mode use
Time frame: at day 90
Hypoglycemia events (serveral hypoglycemia )
Number of serveral hypoglycemia events requiring hospitilisation and/or emergency
Time frame: at day 0
Hypoglycemia events (serveral hypoglycemia )
Number of serveral hypoglycemia events requiring hospitilisation and/or emergency
Time frame: at day 90
Hyperglycemia events
Number of hyperglycemia events requiring hospitalisation and /or emergency
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at day 0
Hyperglycemia events
Number of hyperglycemia events requiring hospitalisation and /or emergency
Time frame: at day 90
Glucose Management Indicator (GMI)
Glucose Management Indicator (GMI)
Time frame: at day 0
Glucose Management Indicator (GMI)
Glucose Management Indicator (GMI)
Time frame: at day 90
Coeffecient of variabilty of Glucose Management Indicator
Coeffecient of variabilty
Time frame: at day 0
Coeffecient of variabilty of Glucose Management Indicator
Coeffecient of variabilty
Time frame: at day 90
Microangiopathic events
Number of microangiopathic events (diabetic retinopathy ,diabetic nephropathy, diabetic neuropathy )
Time frame: at day 0
Microangiopathic events
Number of microangiopathic events (diabetic retinopathy ,diabetic nephropathy, diabetic neuropathy )
Time frame: at day 90